New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia

Deborah A. Thomas, Susan O'Brien, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

The discovery of targeted ABL tyrosine kinase inhibitors has allowed significant advances in the treatment of de novo Philadelphia chromosome (Ph)-positive ALL. Whereas the outcome with standard chemotherapy was previously dismal, the use of imatinib in front-line therapy has improved relapse-free survival and overall survival, even in the absence of allogeneic stem cell transplantation in first complete remission (particularly for those with comorbidities or lack of a suitable donor). However, the emergence of resistance to imatinib presents a new therapeutic, challenge. Novel tyrosine kinase inhibitors with enhanced inhibitory potency against ABL and other kinases may further improve on the results observed with imatinib. Optimal use of these novel agents in the treatment schema of Ph-positive ALL will be paramount in ensuring continued success in the eradication of this disease.

Original languageEnglish (US)
Pages (from-to)183-189
Number of pages7
JournalCurrent Hematologic Malignancy Reports
Volume2
Issue number3
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this